A Study to Evaluate Mepolizumab Withdrawal After Long-Term Use

Mise à jour : Il y a 4 ans
Référence : EUCTR2015-002361-32

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To evaluate whether patients with severe eosinophilic asthma who have received longterm treatment with mepolizumab (at least 3 years) need to maintain treatment with mepolizumab to continue to receive benefit.


Critère d'inclusion

  • Severe Eosinophilic Asthma

Liens